9MW-2921
- Generic Name
- 9MW-2921
Mabwell to Showcase Six Novel Cancer Therapeutics at 2025 AACR Annual Meeting
• Mabwell will present six preclinical studies at the 2025 AACR Annual Meeting in Chicago, highlighting their expanding oncology pipeline with innovative antibody-drug conjugates and T-cell engagers.
• The company's presentations include promising data on novel therapeutics targeting B7-H3, CLDN1, and cadherin 17 for solid tumors, as well as a LILRB4xCD3 bispecific T-cell engager for acute myeloid leukemia.
• Mabwell's research demonstrates significant advances in cancer treatment approaches, including synergistic effects between their B7-H3-targeting ADC and PARP inhibitors, and a new T-cell engager platform optimized for both hematologic and solid tumors.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath